Effectiveness of preemptive therapy with gancyclovir in renal transplant recipients with high risk for cytomegalovirus disease (R-/D+)

Revista de Investigacion Clinica

Volumn 54, Issue 3, 2002, Pages 198-203

  Aranda Verástegui, Francisco ^a   Alberú, Josefina ^a   Soto Ramírez, Luis E ^a   González Aguirre, Humberto ^a   Muñoz Trejo, Teresa ^a   Mancilla, Eduardo ^a   Díliz, Héctor ^a   Correa Rotter, Ricardo ^a   Sierra Madero, Juan ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cytomegalovirus disease; Gancyclovir; pp65 antigenemia; Preemptive therapy; Renal transplantation

Indexed keywords

CREATININE; GANCICLOVIR; IMMUNOGLOBULIN M; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; ANTIVIRUS AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; IMMUNOSUPPRESSIVE AGENT; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOCYTE; PROPHYLAXIS; PROSPECTIVE STUDY; RECIPIENT; SEROLOGY; ADULT; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DISEASE TRANSMISSION; DONOR; DRUG COST; ECONOMICS; EVALUATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEXICO; POSTOPERATIVE COMPLICATION; PREMEDICATION; RISK; TRANSPLANTATION; VIREMIA; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CREATININE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG COSTS; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MEXICO; PHOSPHOPROTEINS; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RISK; TISSUE DONORS; TRANSPLANTS; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 0036049260     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Renal transplantation and graft survival and its influencing factors
2. Infection complications of kidney transplantation
3. Infection in the organ transplant recipient
4. Cytomegalovirus infection in organ transplant recipients
5. Infection in solid organ transplant recipients
6. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
7. The effect of delayed graft function on renal transplant outcome
8. Effect of prophylactic gancyclovir on cytomegalovirus infection in renal transplant recipients
9. Cytomegalovirus prophylaxis in solid organ transplant recipients
10. Preemptive gancyclovir therapy in citomegalovirus seropositive renal transplant recipients
11. Preemptive gancyclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody positive renal transplant recipients. A randomized controlled trial
12. Direct detection of cytomegalovirus in peripheral blood leukocytes: A review of the antigenemia assay and polymerasa chain reaction
13. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes
14. Prevalence of clinically overt cytomegalovirus disease in kidney transplant patients
15. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia
16. Infectious disease complications of renal transplantation
17. Infection in the organ transplant recipient
18. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
19. Newer methods for diagnosis of cytomegalovirus infection
20. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation
21. Cytomegalovirus infection in transplant recipients: The role of tumor necrosis factor
22. Post-transplant lymphoproliferative disorder
23. Detection of cytomegalovirus DNA in sera of liver transplant recipients
24. The role of PCR in the diagnosis and management of CMV in solid organ recipients
25. Quantification of human cytomegalovirus DNA using the polymerase chain reaction